

REMARKS

Claims 1 – 21 and 25 – 40 are pending in the present application. The Examiner has required restriction to one of five groups: Group I, claims 1 – 19, 25 – 27, 33, 34, 36 – 38 drawn to compounds and compositions; Group II, Claims 20, 21, 35 drawn to methods of treating viral infections; Group III, Claims 28 – 29, 31, 39 draw to a multi-component therapeutic regimen for treating viral infections; Group IV, Claims 30 , 40 drawn to pharmaceutical compositions; Group V, claim 24 drawn to methods of making pyridines of Formula 4h.

Applicants wish to bring to the Examiner's attention that Group V, "drawn to methods of making pyridines of Formula 4h" encompasses Claim 32, not Claim 24 as stated in the Restriction Requirement. Applicants request clarification or correction.

In response to the Restriction Requirement, Applicants elect Group I, Claims 1 – 19, 25 – 27, 33, 34, and 36 – 38. Applicants elect the following species: 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide. Applicants submit that claims 1, 2, 3, 5, 6, 7, 9, 10, 13, 15, 17, 18, 19, 25 – 27, 33, 34, 36 – 38 encompass the elected species.

Should any fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

It is respectfully submitted that the present application is in condition for consideration. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: February 5, 2008



Karen L. Prus

Attorney of Record, Reg. No 39,337

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988